Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients aged 18 and up
Patients with maximum serum growth hormone concentration of less than 5 ng/ml
Patients who can successfully complete this study based on appropriate medical judgment or who expect to benefit from this study
Persons who have agreed in writing to participate in this study
Persons who are currently under treatment after being diagnosed with a malignant tumor
Renal function disorder
Proliferative diabetic retinopathy
Persons who carry acromegaly activity
Fertile women who are not pregnant or who do not take appropriate contraceptive measures and whose urine tested positive for hCG (human Chorionic Gonadotropin)
Mental patients and/or drug addicts and alcoholics
Patients who had participated in the other drug study within the last 30 days prior to participating in this study
Patients considered unfit for this study by the attending physician